Mr. Yalong Wang | Epigenetics | Best Researcher Award
Mr. Yalong Wang | The University of Texas MD Anderson Cancer Center | United States
Mr. Yalong Wang is an Instructor in the Department of Epigenetics and Molecular Carcinogenesis at The University of Texas MD Anderson Cancer Center. His scientific journey reflects strong expertise across animal science, cell biology, immunology, and epigenetics. He has contributed significantly to understanding molecular mechanisms in cancer biology, host-pathogen interactions, and protein arginine methylation. His innovative research includes developing pan-methylarginine antibodies, creating SND1 mouse models, and discovering novel methylation reader domains. With prior experience in both academia and biotechnology industries, Mr. Yalong Wang combines leadership and collaborative skills with scientific excellence, driving forward discoveries with clinical and therapeutic implications.
Professional Profile
Education
Mr. Yalong Wang his academic career with a Bachelor’s degree in Animal Science from Shanghai Jiaotong University. He then pursued a doctoral degree in Cell Biology at the University of Chinese Academy of Sciences, where his research uncovered the role of NLRC5 in antigen presentation. Building on this foundation, he continued postdoctoral training in Immunology at the University of Science and Technology of China. His second postdoctoral fellowship was completed at UT MD Anderson Cancer Center, where he specialized in epigenetics and molecular carcinogenesis. This strong and diverse educational background prepared him to bridge fundamental science with translational insights.
Experience
Dr. Wang has a distinguished record in both academia and industry. He began his career as an antibody engineer and project leader in biotechnology companies, where he contributed to therapeutic antibody development. His academic path continued with postdoctoral research in immunology in China, followed by advanced training in epigenetics at MD Anderson Cancer Center. He developed innovative antibody tools, engineered mouse models, and collaborated on drug discovery studies. Currently serving as an Instructor at MD Anderson, he leads projects on methylation readers and cancer regulation. His experience integrates discovery research, translational application, and mentorship of junior scientists.
Research Interests
Dr. Wang’s research centers on epigenetics, immunology, and host-pathogen interactions. He is deeply interested in protein arginine methylation, with a focus on developing antibody tools and identifying novel methylation readers that regulate transcription, RNA splicing, and cancer signaling pathways. His investigations also extend to microbial sensing in the intestine, exploring how deficiencies in helicases such as DHX15 affect antimicrobial defense. Additionally, his studies examine how proteins like SND1 and SART3 influence tumor progression through methylarginine recognition. These research interests bridge fundamental biology with therapeutic opportunities, offering new approaches for treating cancers and immune-related disorders.
Awards
Dr. Wang has received honors recognizing his academic excellence and research potential at multiple stages of his career. During his doctoral studies in China, he was awarded the National Scholarship Excellence Award for outstanding research contributions, along with scholarships from Shanghai Jiao Tong University. More recently, he was recognized internationally with the EMC Travel Award from MD Anderson Cancer Center, acknowledging his impact in the field of epigenetics and molecular carcinogenesis. These honors highlight his consistent ability to produce meaningful scientific advances and his growing reputation as an emerging leader in biomedical research.
Top Noted Publications
Title: NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens
Year: 2012
Cited by: 968
Title: The RNA helicase Dhx15 mediates Wnt-induced antimicrobial protein expression in Paneth cells
Year: 2021
Cited by: 145
Title: Pan-methylarginine antibody generation using PEG linked GAR motifs as antigens
Year: 2022
Cited by: 32
Title: A small molecule antagonist of SMN disrupts the interaction between SMN and RNAP II
Year: 2022
Cited by: 83
Title: Loss of the methylarginine reader function of SND1 confers resistance to hepatocellular carcinoma
Year: 2023
Cited by: 21
Title: SART3 reads methylarginine-marked glycine- and arginine-rich motifs
Year: 2024
Cited by: 5